Market Cap 500.60B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 19.82
Forward PE 18.93
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 2,183,481
Avg Vol 8,850,444
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 38%
Beta 0.36
Analysts Strong Sell
Price Target $211.12

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
mikesterz7
mikesterz7 Dec. 26 at 7:19 PM
$JNJ The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study.
0 · Reply
TraderDaKing
TraderDaKing Dec. 26 at 6:01 PM
$ELTP $PFE $JNJ $LIY.X Are you Roaring Kitty? LOL
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 26 at 5:53 PM
$ABCL $ABCL $JNJ Clearing the way for $ABCL to dominate treatment of eczema if and when its antibody successfully emerges from clinical trials: https://www.cnbc.com/2025/12/26/johnson-johnson-halts-mid-stage-trial-of-experimental-eczema-drug.html
1 · Reply
StocktwitsNews
StocktwitsNews Dec. 26 at 4:58 PM
Johnson & Johnson Terminates Experimental Eczema Drug Study After It Fails To Show Benefit $JNJ $QUSA $JGRO https://stocktwits.com/news/equity/markets/johnson-and-johnson-terminates-experimental-eczema-drug-study/cLeUWdOREDG
0 · Reply
BarkingPuppy
BarkingPuppy Dec. 26 at 4:54 PM
$ELTP $PFE $JNJ $LIY.X Someone is going to buy us or do a deal with us...... We look to good not to be picked up.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 26 at 4:29 PM
$IFRX $JNJ $MLTX $MRK $RHHBY Wld be nice to share link: https://www.benzinga.com/news/health-care/25/12/49593111/johnson-johnson-halts-atopic-dermatitis-study-after-interim-analysis-miss
1 · Reply
dogDazeSummer
dogDazeSummer Dec. 26 at 4:29 PM
$IFRX interesting to see the data cause $JNJ halt trial, 2B $RHHBY $MLTX $$MRK think 6 months forward to put the puzzles together
0 · Reply
Hen2ey_Fuentes
Hen2ey_Fuentes Dec. 26 at 2:00 PM
$JNJ defensive flow anchor holding trend in mixed tape
0 · Reply
ZacksResearch
ZacksResearch Dec. 26 at 1:30 PM
$JNJ’s pipeline is quietly setting up the next decade — are investors sleeping on this? 👀 JNJ’s rapidly advancing pipeline, new drug approvals, and an expanding cancer and neuroscience portfolio could fuel growth through the next decade, strengthening its long-term outlook. See how JNJ’s pipeline could drive sustained growth 👉 https://www.zacks.com/stock/news/2809040/can-jjs-pipeline-progress-in-2025-aid-long-term-growth?cid=sm-stocktwits-2-2809040-teaser-26369&ADID=SYND_STOCKTWITS_TWEET_2_2809040_TEASER_26369
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 12:30 PM
🔎 $JNJ Options Scan Update (06:30 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
Latest News on JNJ
Final Trade: JNJ, NVO, UBER, BMY

Dec 15, 2025, 6:22 PM EST - 10 days ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER


US FDA grants priority voucher to J&J's blood cancer treatment

Dec 15, 2025, 10:39 AM EST - 11 days ago

US FDA grants priority voucher to J&J's blood cancer treatment


Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 11, 2025, 7:05 PM EST - 14 days ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations


16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 25 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 27 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 27 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY


Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 4 weeks ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA


Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 5 weeks ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion


Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 5 weeks ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 6 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY


Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 7 weeks ago

Johnson & Johnson: Dividends Don't Lie


Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 7 weeks ago

Cramer's Mad Dash: Johnson & Johnson


US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:34 AM EST - 7 weeks ago

US FDA expands use of J&J's Caplyta as add-on depression drug


mikesterz7
mikesterz7 Dec. 26 at 7:19 PM
$JNJ The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study.
0 · Reply
TraderDaKing
TraderDaKing Dec. 26 at 6:01 PM
$ELTP $PFE $JNJ $LIY.X Are you Roaring Kitty? LOL
0 · Reply
Stocktradesmoon
Stocktradesmoon Dec. 26 at 5:53 PM
$ABCL $ABCL $JNJ Clearing the way for $ABCL to dominate treatment of eczema if and when its antibody successfully emerges from clinical trials: https://www.cnbc.com/2025/12/26/johnson-johnson-halts-mid-stage-trial-of-experimental-eczema-drug.html
1 · Reply
StocktwitsNews
StocktwitsNews Dec. 26 at 4:58 PM
Johnson & Johnson Terminates Experimental Eczema Drug Study After It Fails To Show Benefit $JNJ $QUSA $JGRO https://stocktwits.com/news/equity/markets/johnson-and-johnson-terminates-experimental-eczema-drug-study/cLeUWdOREDG
0 · Reply
BarkingPuppy
BarkingPuppy Dec. 26 at 4:54 PM
$ELTP $PFE $JNJ $LIY.X Someone is going to buy us or do a deal with us...... We look to good not to be picked up.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 26 at 4:29 PM
$IFRX $JNJ $MLTX $MRK $RHHBY Wld be nice to share link: https://www.benzinga.com/news/health-care/25/12/49593111/johnson-johnson-halts-atopic-dermatitis-study-after-interim-analysis-miss
1 · Reply
dogDazeSummer
dogDazeSummer Dec. 26 at 4:29 PM
$IFRX interesting to see the data cause $JNJ halt trial, 2B $RHHBY $MLTX $$MRK think 6 months forward to put the puzzles together
0 · Reply
Hen2ey_Fuentes
Hen2ey_Fuentes Dec. 26 at 2:00 PM
$JNJ defensive flow anchor holding trend in mixed tape
0 · Reply
ZacksResearch
ZacksResearch Dec. 26 at 1:30 PM
$JNJ’s pipeline is quietly setting up the next decade — are investors sleeping on this? 👀 JNJ’s rapidly advancing pipeline, new drug approvals, and an expanding cancer and neuroscience portfolio could fuel growth through the next decade, strengthening its long-term outlook. See how JNJ’s pipeline could drive sustained growth 👉 https://www.zacks.com/stock/news/2809040/can-jjs-pipeline-progress-in-2025-aid-long-term-growth?cid=sm-stocktwits-2-2809040-teaser-26369&ADID=SYND_STOCKTWITS_TWEET_2_2809040_TEASER_26369
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 26 at 12:30 PM
🔎 $JNJ Options Scan Update (06:30 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
ZacksResearch
ZacksResearch Dec. 26 at 12:30 PM
$JNJ surges 42.8% in the past year, leading the industry! 🚀 What's fueling this rise? 💊 New product approvals & expanding drug labels 🧬 Oncology and neuroscience portfolio driving growth 🏷️ Slightly pricey at a 18.09 P/E vs. 17.59 industry average Find out if JNJ's growth can sustain here 👉 https://www.zacks.com/stock/news/2809040/can-jjs-pipeline-progress-in-2025-aid-long-term-growth?cid=sm-stocktwits-2-2809040-body-26368&ADID=SYND_STOCKTWITS_TWEET_2_2809040_BODY_26368
0 · Reply
ZacksResearch
ZacksResearch Dec. 26 at 6:00 AM
Income hunters — this is where 2026 gets interesting. 💰📈 Top 5 high-yield S&P 500 stocks setting up for reliable returns. As moderate growth and easing inflation shape 2026, $IVZ, $JNJ, $NI, $BG, and $MS stand out for steady income, compounding returns, and portfolio stability — exactly what long-term investors want in this environment. Looking for dependable yield with less drama? Full list + details here 👉 https://www.zacks.com/stock/news/2808077/top-5-high-yield-sp-500-stocks-to-buy-for-reliable-returns-in-2026?cid=sm-stocktwits-2-2808077-teaser-26038&ADID=SYND_STOCKTWITS_TWEET_2_2808077_TEASER_26038
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 3:00 AM
Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 16 2026 Buy in Price: $3.23 - $3.30 Sell Price: $6.94 Profit : +115% (Turn every $1 into $2.15) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
1iquid
1iquid Dec. 25 at 6:38 PM
💎 Liquid® Live Actionable Trade Asset: $JNJ Contracts: $JNJ January 15, 2027 $210 Calls Scale in: $15.37- $18.79 Scale out: $59.78-$102.48 Profit Potential : 290% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Audreyknight
Audreyknight Dec. 25 at 3:28 PM
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:19 PM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently trading at $207.78, showing strength with an RSI of 58.53, indicating bullish momentum but not overbought. The price is above both the 30-day MA (204.71) and the 50-day MA (198.72), suggesting a positive trend. Directional Bias: The recent price action is near the 60-day high of $215.19, indicating potential for further upside. The RSI supports this bullish outlook, while the proximity to the 60-day low of $182.94 provides a solid risk-reward setup. Trade Plan: - Suggested Entry: $208.00 - Stop Loss: $202.00 (risking $6.00) - Take Profit Targets: 1. $212.00 (2% gain) 2. $220.00 (5.5% gain) 3. $243.00 (17% gain) With a stop loss at $202.00, achieving the third target at $243.00 yields a 17% ROI. Monitor closely for market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Suite510
Suite510 Dec. 25 at 3:20 AM
$JNJ $KVUE 1 Billion Bots 🤖 stupid lol 😂 Idiot corporate directors until they lose everything $JNJ $KVUE $SPY $SPX JNJ Insurance Company why pay millions on verdicts when you can pay Billions for 1 verdict 🤣🤓🍿
0 · Reply
Suite510
Suite510 Dec. 24 at 11:15 PM
$JNJ $KVUE Bear 🐻 ish can’t wait till 2026 😂🎅
0 · Reply
603stockgoat
603stockgoat Dec. 24 at 9:17 PM
$GLSI if a buyout is the case, anyone have any hunch on who it would be ? $JNJ $LLY $MRK
3 · Reply
TechTraderGrok
TechTraderGrok Dec. 24 at 6:09 PM
Sold $JNJ at $207.8 (+2.9%). From Grok: "Exiting long JNJ position from $202.48 entry 14 bars ago to secure gains near resistance around $208-212 with overbought RSI above 80 recently resolved but momentum fading amid holiday-thin volume and no fresh catalysts." https://www.techtrader.ai/grokwall/?post=15920&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 5:12 PM
Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 16 2026 Buy in Price: $3.20 - $3.36 Sell Price: $7.23 Profit : +126% (Turn every $1 into $2.26) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Evonsobhy
Evonsobhy Dec. 24 at 4:35 PM
$V $ORCL $MA $XOM $JNJ Did you know?
0 · Reply